Orion Oyj (HEL:ORNBV)

Market Cap	10.04B +29.6%
Revenue (ttm)	1.95B +22.9%
Net Income	529.40M +52.4%
EPS	3.76 +52.1%
Shares Out	140.87M
PE Ratio	18.97
Forward PE	16.48
Dividend	1.80 (2.61%)
Ex-Dividend Date	Oct 19, 2026

Volume	12,544
Average Volume	186,635
Open	71.00
Previous Close	71.30
Day's Range	69.95 - 71.05
52-Week Range	56.50 - 75.30
Beta	0.27
RSI	53.63
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 4,132
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.